Randomize Trial of Cisplatin plus Gemcitabine with either Sorafenib or Placebo as First-line Therapy for Non-small Cell Lung Cancer

Article Chinese OPEN
Yan WANG; Lin WANG; Yutao LIU; Shufei YU; Xiangru ZHANG; Yuankai SHI; Yan SUN;
  • Publisher: Chinese Anti-Cancer Association; Chinese Antituberculosis Association
  • Journal: Chinese Journal of Lung Cancer (issn: 1009-3419, eissn: 1999-6187)
  • Publisher copyright policies & self-archiving
  • Subject: Lung neoplasms | Sorafenib | Response | RC254-282 | Chemotherapy | Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    mesheuropmc: neoplasms

Background and objective Platinum-based chemotherapy doublets reached an efficacy plateau in nonsmall-cell lung cancer (NSCLC). This randomized controlled study prospectively assessed the efficacy and safety of cisplatin plus gemcitabine with either Sorafenib or placebo... View more
Share - Bookmark